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Abstract  
Recently, the National Institute of Mental Health (NIMH) introduced the Research Domain 
Criteria (RDoC) initiative to address two major challenges facing the field of psychiatry: (1) the 
lack of new effective personalized treatments for psychiatric disorders, and (2) the limitations  
associated with categorically-defined psychiatric disorders. While the potential of RDoC to 
revolutionize personalized psychiatric medicine and psychiatric nosology has been 
acknowledged, it is unclear how to implement RDoC in naturalistic clinical settings as part of 
routine outcomes research. In this paper we present the major RDoC principles and then show 
how these principles are operationalized in the Menninger Clinic’s McNair Initiative for 
Neuroscience Discovery-Menninger & Baylor College of Medicine (MIND-MB) study. We 
discuss how RDoC-informed outcomes-based assessment in clinical settings can transform 
personalized clinical care through multimodal treatments. 
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The need for RDoC 
Effective treatments and policies are lacking for adolescents and adults with serious 
mental illness (SMI; i.e., treatment refractory neuropsychiatric disorders). Because tightly 
controlled efficacy studies restrict the capacity to provide personalized care, they may also 
restrict treatment response. Moreover, health insurance and public sector mental healthcare 
systems rarely allow for more than very brief psychiatric hospitalizations to focus primarily on 
stabilization. Thus, the majority of people with SMI are not afforded the time in treatment 
necessary to understand and treat their complex clinical symptoms and functional impairments. 
Offering personalized care means recognizing that for reasons of genetic makeup and personal 
history, people respond differentially to specific treatments and that poor response to one 
treatment does not necessarily imply poor response to another, or deny the possibility of 
potentiation through combinations of multimodal treatments over time.  
In addition to the challenges facing personalized clinical care for SMI, the publication of 
the 5th edition of the Diagnostic and Statistical Manual for Mental Disorders in 2013 by the 
American Psychiatric Association was preceded by controversy and contentious debate (Regier, 
2007a, 2007b; Saunders, 2006; Widiger & Simonsen, 2005). Despite the hopes that the practice 
of psychiatric diagnosis would be revolutionized, the knowledge base in the field was not judged 
sufficient to justify moving beyond the established tradition of  diagnosing mental disorders 
based on clinical observation and patients’ phenomenological symptom reports.  In addition, the 
polythetic and dichotomous (categorical) diagnostic system was, for the most part, retained. In 
psychiatry (unlike other disciplines in medicine) we rely solely on the patient’s subjective report, 
and on clinical observation, for diagnosis and treatment planning. In other words one could say 
that in psychiatry the disease is diagnosed as the symptom. Thus anxiety, for instance, is both the 
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diagnosis and its symptom. In general medicine, by contrast, when a patient presents with 
excessive thirst and frequent restroom breaks, the physician might order a blood glucose level 
test to confirm or dispute a diagnosis of diabetes, acknowledging that the behavioral phenotype 
(excessive thirst and frequent restroom breaks) may be associated with a variety of underlying 
conditions and that a direct mapping of subjective patient report to pathophysiology may clarify 
the disorder. In psychiatry, when a patient presents with anger outbursts, affective instability, a 
history of suicide attempts, alcohol abuse and relationship problems, he/she  meets  five out of 
nine DSM-5 criteria for borderline personality disorder and the physician diagnoses the disorder 
without any information about underlying biological processes. 
The DSM system furthermore conceptualizes diagnoses as polythetic dichotomies 
(Oldham, 2005).  The polythetic nature of diagnoses means that patients can present with only a 
portion of the criteria that define a disorder and will receive a given diagnosis as long as the 
patient has met the symptom threshold (Silverman & Krueger, 2014). Thus, staying with the 
example of borderline personality disorder, another patient may present with chronic feelings of 
emptiness, identity disturbance, paranoid ideation, abandonment fears and shoplifting and also 
meet criteria for borderline personality disorder. Indeed, there are 256 different combinations of 
symptoms that all result in a person receiving a diagnosis of borderline personality disorder 
(Skodol, Bender, Gunderson, & Oldham, 2014).  For PTSD in the DSM-IV there were 1,750 
different combinations of symptoms that led to a diagnosis, and in DSM-5 it is over 10,000 
(Rosen, Lilienfeld, Frueh, McHugh, & Spitzer, 2010).  Therefore, often, patients with the same 
diagnoses can have very different symptom patterns, thereby calling into question the validity of 
the disorder. Consequently, patients may be misdiagnosed or needlessly diagnosed with one or 
more comorbid disorders (Hyman, 2007). The patient described above presenting with anger 
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outbursts, affective instability, a history of suicide attempts, alcohol abuse and relationship 
problems could potentially be diagnosed with bipolar II disorder or a substance use disorder or 
both.  Conditions have such marked overlap in symptoms that similar features may count 
towards supposedly different diagnoses. 
A dichotomous (categorical) diagnostic system utilizes a threshold of symptoms to 
establish a diagnosis. Thus, in our earlier example, a person must meet five (or more) out of nine 
criteria for borderline personality disorder. If a patient presented with a history of suicide 
attempts, affective instability and anger outbursts (three criteria) the patient would not receive a 
diagnosis.  In this way, the diagnoses are considered as a yes/no distinction, with no room in the 
rubric for gradations of a disorder (Silverman & Krueger, 2014), yet a real possibility exists that 
a patient would not receive needed services. Moreover, diagnostic thresholds utilized in the 
categorical approach often are arbitrary, while the variability both above and below diagnostic 
thresholds can be clinically meaningful (Kessler et al., 2003) and does not mirror the way 
practicing clinicians use the categories in everyday practice (Kim & Ahn, 2002; Mussigbrodt et 
al., 2000; Reed, Mendonca Correia, Esparza, Saxena, & Maj, 2011). 
The current DSM system, characterized by polythetic and dichotomous (categorical), 
criteria-based diagnoses based on patients’ phenomenological symptom reports, was 
implemented for the first time in the Third Edition of the Diagnostic and Statistical Manual 
(DSM-III) in 1980, and refined in DSM-IV-TR in 2000.  In many ways, this diagnostic system 
has served clinical practice and research well (Silverman & Krueger, 2014). We now have an 
improved understanding of many disorders and progress has been made in the development and 
dissemination of empirically validated and manualized treatments, allowing for improved quality 
of care for psychiatric patients. Accordingly, the diagnostic categories represented in the DSM-5 
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still reflect contemporary consensus for the diagnosis and treatment of mental disorders, and are 
used in some countries for insurance billing, as standard requirements for medication trials, and 
in the U.S. as a predominant standard in the NIMH grant review process.  
However, the reliance on polythetic and dichotomous (categorical) diagnoses at the level 
of the behavioral phenotype alone has impeded the use of advances in genomics, 
pathophysiology, psychopharmacology and behavioral science to aid in the diagnosis and 
treatment of psychiatric disorders (Insel et al., 2010; Insel, 2014). For example, the current 
funding crisis in the development of new psychoactive agents has been unequivocally attributed 
by some to inadequacies of the currently used psychiatric diagnostic system: “The data are in, 
and it is clear that a massive experiment has failed. A major barrier to progress is the current 
state of nosology in psychiatry. A new taxonomy is a prerequisite for meaningful progress. 
Today, few would argue that syndromes such as schizophrenia and depression are single, 
homogeneous diseases. And yet when it comes to clinical research, including clinical trials, both 
are still almost always treated as such” (Fibiger, 2012) (p.649). And while biological correlates 
of psychiatric disorders have been identified, variations in neurobiological systems or specific 
genes do not associate one-to-one with categorically defined mental disorders but, instead, cut 
across a variety of disorders. Moreover, it has also been argued that reliance on polythetic and 
dichotomous diagnoses may have led to a dehumanization of psychiatric practice by reducing the 
diagnostic process to a check of the presence or absence of symptoms (Maj, 2014). 
One solution to this problem is to develop better diagnostic tests as we have argued 
elsewhere (Sharp, Monterosso, & Montague, 2012). A complementary initiative would be to 
depart from the categorical classification system of mental disorders and to “develop new ways 
of classifying mental disorders based on dimensions of observable and neurobiological 
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measures”. Indeed, this statement is articulated in the NIMH strategic plan and led to the 
launching of the Research Domain Criteria Project (RDoC) in 2011 and has generated much 
discussion in the scientific literature (see for example Maj, 2014). 
The principles of RDoC 
RDoC is guided by three principles. First, in contrast to the categorical DSM system, 
RDoC is conceived as a dimensional system spanning the range from normal to abnormal. 
Second, RDoC is agnostic about DSM categories. RDoC seeks to “carve nature at its joints” by 
generating classifications stemming from basic behavioral neuroscience. Whereas psychiatry 
typically starts with a DSM diagnosis and then seeks neurobiological underpinnings, RDoC 
begins with current knowledge of behavior-brain relations and links them to clinical phenomena 
(Insel et al., 2010). RDoC uses multiple levels of analysis in studying functional domains from 
genes to the level of self-report.  Finally, recruiting from large psychiatric clinics across a broad 
spectrum of psychiatric diagnoses to study, for example, fear circuitry provides an alternative to 
the recruitment of individuals with circumscribed symptom profiles (Insel et al., 2010).  
To operationalize the above principles, RDoC provides a matrix with rows that cover five 
domains of function: Negative Valence Systems, Positive Valence Systems 
(approach/motivation), Cognitive Systems, Systems for Social Processes and Arousal/Regulatory 
Systems. Each of the domains is associated with relevant constructs selected for the potential that 
a particular brain circuit or area could reasonably be specified that implements that dimension of 
behavior. For instance, the Positive Valence Systems include the following constructs: reward 
valuation, effort valuation, reward expectancy/prediction error, initial responsiveness to reward, 
sustained responsiveness to reward, reward learning, and habit. The columns of the matrix 
8 
 
8 
 
represent seven different units of analysis including  Genes, Molecules, Cells, Neural Circuits, 
Physiology, Behaviors and Self-report. 
Operationalizing RDoC in naturalistic clinical research settings 
While it is acknowledged that the problems with the current nosological system need to 
be addressed in naturalistic clinical settings (Maj, 2014), operationalizing RDoC principles in 
naturalistic clinical research settings can be challenging, partly because there is little precedent to 
draw from in psychiatry. NIMH has thus far approved about 40 RDoC studies. As the findings 
and methods of these studies are becoming public, we are developing a set of criteria that may 
guide the implementation of RDoC research in naturalistic clinical settings. Below, we outline 
these criteria, followed by a discussion of the implementation and progress of our project.   
Dimensional approach to psychopathology. Studies examining the biological markers 
associated with psychiatric disorders have typically made use of case-control study designs using 
carefully screened and relatively small samples with little generalizability to actual psychiatric 
populations. In these studies it is unclear whether demonstrated group differences reflect 
symptom- or disorder-specific associations or nonspecific associations with latent dimensions of 
psychopathology. We must depart from research strategies that focus on a single diagnosis in 
isolation. Instead, the neurobiological basis of RDoC constructs must be examined using state-
of-the-science models of dimensional structure of psychopathology in real-life psychiatric 
settings.  
Recently, several models have been published of empirically defined dimensions of 
psychopathology that can be applied in this context. For instance, an internalizing-externalizing 
spectrum model has received considerable attention as a potential theoretical framework for 
understanding co-occurring psychiatric disorders (Krueger, 1999; Krueger, Caspi, Moffitt, & 
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Silva, 1998; Krueger, McGue, & Iacono, 2001).  Confirmatory factor analysis is used to fit 
measurement models for psychopathology that can be correlated with latent neural circuits or 
variables across different units of analyses. For this strategy, large sample sizes will be needed, 
as required by the latent trait models used to extract underlying psychopathology factors. It 
would also be important to make use of diagnostic tools that do not employ skip-out rules since 
the full criteria content will be used to extract factors.  
Sampling. As discussed above, the over-reliance on case-control and randomized control 
trial study designs in psychiatry may partially explain the lack of progress in understanding 
underlying neurobiological processes associated with broad, cross-cutting dimensions of 
psychopathology. The field must develop a broader appreciation for scientific investigations 
utilizing representative psychiatric populations who present complex and multi-faceted symptom 
profiles, rather than relying so heavily on studies using carefully selected samples that bear little 
or no resemblance to real patients (Kessler et al., 2003). Therefore, actual patients in real-life 
settings need to be recruited for studies. In addition, because RDoC favors a dimensional system 
spanning the range from normal to abnormal, recruitment of real-life patient populations needs to 
be supplemented by the recruitment of non-treatment seeking individuals from the community.  
The aim is to capture the normal distribution of underlying biologically-based constructs rather 
than skewed distributions characteristic of only one end of the psychopathology spectrum. 
Multiple units of analyses. Essential to any RDoC project is the collection of data across 
multiple units of analyses. For instance, DNA samples can be collected in order to test the 
specific impact of gene variants and epigenetics on psychopathology through the mediating 
effects of domain constructs. Conversely, studying a behavioral endophenotype such as rejection 
sensitivity should include performance-based assessment of behavior, neuroimaging, and 
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genetics. A relatively novel area of research highlights the influence of gut microbiome on 
psychiatric disease (Foster & Neufeld, 2013) . Thus, a robust RDoC study may include the 
assessment of genes, systems that interact with the brain (e.g. gut microbes), circuits, behavior 
and self-report data. 
Domains with the potential for cross-cutting associations across several psychiatric 
disorders. Essential to the success of an RDoC project would be choosing domains of function 
that have the potential for cross-cutting associations across several psychiatric disorders. For 
instance, the Positive Valence System is particularly interesting for thinking about divergence of 
the externalizing and internalizing factors underlying common mental disorders such that 
externalizing disorders are often associated with hyper-functioning of the Positive Valence 
System, while internalizing disorders are often associated with its hypofunctioning (Sharp et al., 
2012). Because of these strong hypothesized links to psychopathology, and because the Positive 
Valence System is one of the research domain criteria most often associated with well-validated 
and well-used neuroimaging paradigms, this approach provides a tractable starting point for 
testing cross-cutting hypotheses. 
The potential for the availability of a public use data set for qualified research 
groups. Because an RDoC study would typically include a large sample of individuals 
unconstrained by traditional diagnostic boundaries, and data across multiple levels of analyses, 
an RDoC project should make available its data for analyses by other qualified research groups. 
In addition, the ideal RDoC study would provide a platform for future RDoC collaborations and 
extensions based on existing infrastructure. 
Developmental aspects. Developmental influences on phenotypic plasticity need greater 
elucidation. Extant research on the structure of psychopathology focuses on individuals who 
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report symptoms within a specified period. Ambiguity comes from mixing single-episode, one-
off cases with recurrent and chronic cases.  These differ in the extent of their comorbid 
conditions, the severity of the conditions and potentially also the etiology of the conditions.  This 
problem appears to be the case for depression, alcohol-use disorders and psychotic experiences 
(Jackson & Sartor, in press; Monroe & Harkness, 2011; van Os, Linscott, Myin-Germeys, 
Delespaul, & Krabbendam, 2009). Comorbidity is sequential as well as cross-sectional. For 
instance, generalized anxiety disorder and major depressive disorder are linked to each other 
sequentially (each disorder increases the likelihood of developing the other) (Copeland, 
Shanahan, Costello, & Angold, 2011; Kessler et al., 2011; Moffitt et al., 2007).  In order to 
explain why some individuals who initially present with panic attacks go on to develop 
obsessive-compulsive disorder, bipolar disorder or psychosis  we need to take account of both 
concurrent and sequential comorbidity when evaluating the structure of psychopathology. This 
requires a developmental approach. 
Within a developmental approach, adolescence, which is defined as the transition phase 
between childhood and adulthood , is a developmental period of immense biological and social 
change (Nelson, Leibenluft, McClure, & Pine, 2005). It is also a time of increased rates of 
accidents, alcohol and drug use, pregnancy, depression, suicide and violence (Crone & Dahl, 
2012). Adolescence is a time of increased risk for psychopathology as evidenced for instance by 
the National Comorbitidy Survey Replication (N = 9,000) that demonstrated that the peak age of 
onset for all mental disorders is 14 years (Kessler, Chiu, Demler, Merikangas, & Walters, 2005). 
Evidence suggests that the increased risk for the emergence of psychopathology is related to 
anomalies or exaggerations of typical adolescent maturation processes in interaction with unique 
psychosocial or biological environments (Paus, Keshavan, & Giedd, 2008). In addition, mental 
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disorders are increasingly viewed as neurodevelopmental disorders (Dahl, 2004; Forbes & Dahl, 
2005), necessitating consideration of developmental aspects in the context of the RDoC 
framework. While prospective follow-up studies are ideal in this regard, important new 
information can be gleaned from studying RDoC constructs cross-sectionally across 
developmental epochs to identify unique neurobiological correlates of RDoC constructs. 
Treatment outcome in naturalistic settings. RDoC holds great potential for identifying 
biomarkers and behavioral indicators for recovery from or improvement in mental illnesses. 
Biomarkers refer to characteristics that are measured objectively as an index of a pathogenic 
process or as a response to treatment (Carter et al.). While evidence is emerging in support of 
several domains of function (e.g. reward-related brain function as a predictor of treatment 
response in depression (Forbes et al.), these studies typically ignore the comorbidity of real-life 
psychiatric cases. Taking a dimensional cross-cutting approach to examining treatment response 
from the bottom-up (that is, brain function predicting treatment response across different 
disorders), would significantly move the field forward.  For example, a recent study found that 
children with one or two copies of the nerve growth factor gene (NGF rs6330) T allele were 
significantly more likely to be free of their primary anxiety diagnosis after completing a course 
of cognitive behavioral therapy (Lester et al., 2012).  
Operationalizing RDoC in naturalistic treatment settings 
Consistent with the criteria above, in 2008 we developed a strategic vision for the 
research programs at The Menninger Clinic “to take advantage of the opportunity for 
longitudinal research, specifically to conduct important studies on clinical outcomes, disease 
course, economic aspects of mental illness, neuroimaging, genetics, and pharmacogenetics (p. 
255)” (Frueh, Oldham, & Fonagy, 2009), working with multidisciplinary research teams.  In 
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September 2014, this vision expanded to allow for the collection of fecal samples to better 
understand of the inter-relationship between gut biomarkers and psychiatric disease, illness 
burden, and/or response to treatment. Building on The Clinic’s tradition of research, and with 
strong institutional commitment from leadership and collaborative relationships with 
investigators at Baylor College of Medicine (BCM) and the University of Houston, we 
developed a research program that fits into the RDoC rubrics and with its overarching goal, 
naming it the Menninger Clinic’s McNair Initiative for Neuroscience Discovery-Menninger & 
Baylor College of Medicine (MIND-MB) study.  We are supported in this effort by an annual 
budget of approximately $2 Million, with funds provided by The Menninger Clinic, the 
Department of Psychiatry at Baylor College of Medicine, the McNair Medical Institute, and 
many other local foundations and donors.   
Research participants. The Menninger Clinic admits approximately 1,000 patients per 
year who typically stay for 6-8 weeks on one of 5 units. Over the course of 3 years, we aim to 
recruit and scan 1,500 inpatients at Menninger across adult and adolescent units to include 12-65 
year olds (including approximately 210 adolescents), in addition to 250 patients from outpatient 
clinics in Houston, as well as 250 non-treatment seeking individuals from the community. There 
are no exclusion criteria for the genetic or gut microbiome portions of the study. Exclusion 
criteria for the fMRI protocol include the usual fMRI exclusions.  
All patients admitted to The Menninger Clinic have the opportunity to participate in the 
study. Thus far, the response rate for participation to date is 73%. Gender is equally distributed 
among adult inpatient units (50% male, 50% female), yet adult males volunteer and complete the 
study at a slightly higher rate (58%) than females (42%).  The average age of adult subjects is 
31.35 (SD=11.97).  The adolescent sample is currently comprised of 46% males and 54% 
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females with an average age of 15.54 (SD=1.61). Typical reasons for non-participation include 
disinterest, claustrophobia, and planned brief treatment.   
fMRI task. Consistent with RDoC criteria as discussed above, we have elected a simple 
reward conditioning paradigm as the first task to examine domain function in a cross-cutting 
way. This task will elicit brain responses in several brain areas, but most importantly in the 
striatum. The striatum is the input structure of the basal ganglia and is responsible for the 
processing of affective stimuli such as rewards (Delgado, 2007). The striatum can be subdivided 
into two components. The dorsal striatum consists of the dorsal caudate nucleus and 
putamen, and receives extensive projections from dorsolateral prefrontal cortex as well as other 
surrounding frontal regions. The ventral striatum consists primarily of the nucleus 
accumbens, along with ventral portions of the caudate and putamen, and receives extensive 
projections from the ventral frontal regions. The ventral striatum also has extensive connections 
with limbic areas implicated in emotional processing. The dorsal and ventral striatum therefore 
are considered to be functionally distinct with the ventral striatum involved in affective and 
motivational processing while the dorsal striatum is involved in more cognitive or sensorimotor 
function (Delgado, 2007; Haber, Fudge, & McFarland, 2000; Strathearn, 2011).  Anomalies in 
activation of the striatum have been associated with both internalizing and externalizing 
disorders. The simple reward conditioning task selected have been shown to activate striatal 
activity (maximally in the putamen) (McClure, Berns, & Montague, 2003) as well as the 
habenula (Salas, Baldwin, de Biasi, & Montague, 2010), a brain center for the processing of 
negative events (Matsumoto & Hikosaka, 2007). This task maps on to the RDoC domain 
constructs of positive (initial response to reward, sustained response to reward, 
expectancy/reward prediction error) and negative (frustrative non-reward) valence subdomains.  
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To complement task-based fMRI we chose two techniques. First, we will perform 
Resting State Functional Connectivity (RSFC) to assess the functional connectivity among 
different areas of the brain (Biswal et al., 2010). RSFC anomalies associated with psychiatric 
disorders have been shown for depression (Guo et al., 2013) and addiction (Kelly et al., 2011). In 
a first round of analysis, we found a difference in inter-hemispherical insular RSFC in patients 
suffering from drug abuse, when compared to psychiatric patients that were matched for several 
parameters but did not suffer from drug abuse (Viswanath et al., 2015). Second, we will perform 
a Diffusion Tensor Imaging (DTI) experiment to measure white matter tracts in the brain. DTI 
will allow us to study the white matter tracts that connect different areas of the brain. RSFC and 
DTI data will be analyzed both as whole brain data driven comparisons and using regions of 
interest derived from the literature and from our own data (for example, results from the reward-
related task may suggest regions of interest to study in RSFC and DTI).  
 Genetic data. Consistent with the RDoC principle of collecting data at multiple units of 
analysis, two blood draws are performed by either a trained assistant or a certified phlebotomist. 
All samples are transported to the Psychiatric Genetics Laboratory at BCM/Veterans Affairs 
Medical Center, except for the samples from adolescents. These samples are sent to the Rutgers 
Cell and DNA Repository in New Jersey where DNA will be extracted and lymphocytes 
cyropreserved. If we are unable to collect a blood sample, a saliva sample is used. The first draw 
occurs when a patient first enters the study and a second draw is taken at the conclusion of 
treatment. The second draw is done to serve as a quality control measure to confirm the identity 
of the first blood sample and to assess genotyping quality and reproducibility. In addition, the 
second sample will allow us in future studies to assess changes in epigenetic markers, such as 
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DNA methylation and chromatin structure, which have been shown to change in response to the 
environment and may change in response to the therapy received at Menninger.  
 Initially, specific variants in several candidate genes that have been shown in human or 
animal studies to be involved in neurological pathways of psychiatric diseases, in vulnerability to 
develop a psychiatric disease, or in response to pharmacotherapy will be evaluated. In the first 
phase of the study, variants in the candidate genes will be genotyped and examined for 
association with the specified phenotypes and possible gene by environment interaction (GxE). 
A GxE study will be conducted to determine if the influence of the genetic variants on phenotype 
is different depending on patient history, such as childhood abuse. To avoid statistical bias due to 
population structure, data derived from ancestry informative markers will be evaluated for 
potential population. In the second phase of this study, gene effects and gene by environment 
interactions will be analyzed using next generation sequencing technology. 
Microbiome data 
Again, in line with RDoC principle of collecting data across multiple units of analysis, we collect 
fecal samples from adult and adolescent patients who agree to participate in this facet of the 
research project at Menninger. The microbes that reside in the human gastrointestinal tract form 
communities, and these communities differ among between people. Variations are determined by 
several factors such as nutrition or physiology and have an impact in health and disease, 
including psychiatric illness.   
After collecting stool samples, nucleic acid (gDNA and/or RNA) will be isolated.  
Nucleic acid samples will be sequenced on a variety of platforms (i.e. Roche 454, Illumina Hi-
Seq) to generate sequence information, allowing for the identification of bacteria/viruses present 
in the samples. Gene expression studies will be confirmed by RT-PCR on RNA samples. Note, 
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the nucleic acids will be stored until completion of the study and will be discarded in an 
appropriate manner at that time.  
Diagnostic and symptom assessments. The Structured Clinical Interview for DSM-IV 
Disorders (SCID I; 44) and the Structured Clinical Interview for DSM-IV Personality Disorders 
(SCID-II; (First, Spitzer, Gibbon, Williams, & Benjamin, 1994) are administered and all criteria 
individually coded without applying any skip-out rules. In addition, self-report and interview-
based assessments are completed at admission with symptom and functional measures repeated 
at 2 week intervals during hospitalization and at post-discharge follow-up.  All psychiatric 
assessment measures are integrated into treatment planning and monitoring of patient care as an 
element of quality improvement. Constructs assessed include: functional disability and well-
being (Bech, Olsen, Kjoller, & Rasmussen, 2003; Ustun, Kostanjek, Chatteerji, & Rehm, 2010), 
substance abuse (Organization, 2010), suicide-related behaviors (Posner et al., 2011), depression, 
anxiety and somatization (Kroenke, Spitzer, Williams, & Lowe, 2010), affect regulation (Gratz 
& Roemer, 2004), and personality traits of the five factor model (John, Naumann, & Soto, 2008). 
Self-report assessments of Positive Valence System. Several self-report measures of 
Positive Valence Systems are included in the battery. The Barratt Impulsiveness Scale (Barratt, 
1959), 11th revision (Patton, Stanford, & Barratt, 1995) is a 30-item self-report instrument 
designed to assess the personality/behavioral construct of impulsiveness. The Behavioral 
Inhibition Scales/Behavioral Activation Scales (Carver & White, 1994) is a self-report measure 
consisting of 20 questions that traditionally comprise 4 separate scales: behavioral inhibition, 
behavioral activation (goal-directed motivation), reward responsivenss (response upon receipt of 
reward), and fun-seeking (desire for novel rewards). 
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Procedures. Figure 1 summarizes the recruitment, assessment and scanning of patients 
and community participants.  
Figure 1 
This broad-based multidimensional assessment approach of overarching domains of 
psychological functioning is particularly relevant to the RDoC.  In addition the study was 
designed to assess the potential neurocognitive and epigenetic effects of an intensive course of 
treatment. A second fMRI of RSN, DTI and task-related functional imaging allows for 
assessment of change and resting state networks as well as the major neural circuits including 
those of disappointment and reward, positive and negative valence systems, and social cognition. 
A second blood draw at 21 days after the initial blood draw (pending IRB approval) will allow us 
to assess potential epigenetic changes by studying the methylation of targeted genes.  
Concluding remarks 
The validity of DSM-based psychiatric disorders has been called into question (Kendell, 
1989) providing the rationale for RDoC. This is not to say that classification of all the major 
psychiatric disorders is arbitrary. Cross-cultural similarities in symptom expression and evidence 
for heritability suggest that DSM criteria identify real conditions, even if they do so imprecisely 
(Hyman, 2007). And it is also not to say that RDoC is not without its limitations. For example, 
RDoC constructs, as defined, appear to be quite distant from clinical phenomena, potentially 
rendering them of limited value in describing or defining psychopathology (Maj, 2014). Related, 
the relationship between RDoC philosophy and clinical reality is unclear; for example, patients 
do not present to the psychiatrist with their genotype or biosignature, but with their phenotype 
(Jablensky & Waters, 2014). Thus, until biology has cultural currency, we will to some extent 
always be relying on the subjective accounts of our patients’ symptoms as a first line of inquiry. 
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However, there is room for improvement, but these changes need to be empirically motivated. In 
this paper, we have provided an example of implementing RDoC aims in a naturalistic clinical 
research setting. Successful implementation of this program of research could provide important 
public access data on the correlates of mental disorder and treatment response across and within 
domains of functioning.  
Our objective is to develop clinically valid dimensions of individual variation, and 
clusters of individuals (population sub-groups with common trajectories of ontogenesis) that 
provide a much greater fit with underlying neural networks and neurocognitions than has been 
achieved.  We will pursue a data-driven (bottom-up) multidimensional approach to improve the 
precision of clinical measurement. We recognize that a multidimensional approach, however 
descriptive, will remain essentially unhelpful if it cannot be applied to prediction of such things 
as course of illness and treatment outcome.  Accumulating evidence suggests that disorders are 
positively correlated not just at the disorder level (comorbidity/co-occurrence), but substantially 
so at the spectrum level (Externalizing and Internalizing spectra are correlated at around r=0.5 
and the Internalizing and Thought Disorder spectra at r=0.6). Thus, it seems that  propensities to 
specific forms of psychopathology (e.g., Internalizing vs. Externalizing) and propensity to 
develop any and all forms of common psychopathologies  may be inherited or acquired and 
biological studies informed by RDoC must aim to identify such generic propensities as well as 
spectra and syndrome level mechanisms (Caspi et al., 2014; Jablensky & Waters, 2014). As 
some of these underlying correlations may be more apparent when individuals are studied over 
time, we consider it essential to adopt a developmental approach and consider systematic 
sampling across age groups as a critical feature of our research protocol.  Characterizing specific 
domains within clinical phenotypes over time of treatment and follow-up enhances precision and 
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validity. This sentiment is consistent with recent reflection on the clinical utility of the RDoC 
framework which suggests that RDoC will achieve its ultimate goal only if can produce a set of 
behavioral and biological measures whose reliability and sensitivity and specificity in predicting 
treatment (and other outcomes) improves over current symptom-based measures (Cuthbert, 
2014; Maj, 2014). 
It is important to note that a neural mechanisms-oriented approach such as we suggest 
here is perfectly consistent with the person-centered approach which is increasingly replacing the 
‘horse race’ paradigm embodied in traditional RCT methodology. A person-centered neural 
mechanism-based approach in line with the emerging personalized medicine movement within 
psychiatry (Myers & Nemeroff, 2010; Ozomaro, Wahlestedt, & Nemeroff, 2013), may be able to 
answer the ‘What works for whom, how, and under what circumstances?’ question which 
diagnosis based approaches have sadly failed to fully elucidate (Fonagy et al., in press; Roth & 
Fonagy, 2005).  
We hope that the approach recommended here will help overcome the lack of progress 
not only in psychopharmacology, but the rather similar picture which is emerging from the 
psychosocial treatment literature.  Since 1975, meta-analyses have not found it easy to show 
superiority for any bona fide psychotherapy over any other and the literature has not highlighted 
specific techniques that account for change, and so called common factors account for a 
considerable proportion of the observed variance in outcome (American Psychological 
Association, 2012; Benish, Imel, & Wampold, 2008; Imel, Wampold, Miller, & Fleming, 2008; 
Lutz, Leon, Martiniwitch, Lyons, & Stiles, 2007; Miller, Wampold, & Varhely, 2008; 
Spielmans, Pasek, & McFall, 2007; Zuroff, Kelly, Leybman, Blatt, & Wampold, 2010).  
Underlying this lack of specificity lies a paradox, namely that for the findings of RCTs to be 
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generalizable they have to gather samples that resemble the ‘normal’ clinical population 
(effectiveness studies), but for the findings to be replicable and interpretable the sample should 
not be obscured by comorbidity and concurrently administered treatments (efficacy studies). The 
heterogeneity of even such ‘pure’ samples in terms of the likely underlying causes leads 
treatment developers to take somewhat of a scatter gun approach trying to address a wide range 
of problems as part of a single manualized treatment package, much of which may not be 
relevant to the problems presented by a specific patient.   
Taken together, RDoC has the potential to revolutionize not only our diagnostic 
nosology, but our ability to more effectively treat our patients. While no system is perfect, RDoC 
may provide a useful complement to the current diagnostic system (First, 2014; Maj, 2014) and 
our hope is that a research program as described here would facilitate a type of cross-walk 
between traditional and alternative approaches to psychopathology. Mostly, it is our hope that 
MIND-MB will uncover the multiple multi-modal pathways to recovery, thereby informing 
personalized psychiatric medicine for patients and families.  
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Figure 1. Operationalizing RDoC in a naturalistic treatment setting 
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